This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M35.3 | Special Copayment Reduction: V139 (rare disease special copayment reduction) |
| B. Synonyms | Polymyalgia rheumatica (PMR), shoulder girdle-pelvic girdle myalgia |
| C. Adult onset | Likelihood of first onset in adulthood: very high (practically an adult-only disease) — it almost never occurs under age 50, and the median age of onset is about 70~73 years. It is a disease of the elderly, with first onset after age 60 accounting for more than 85% of all cases. |
| 1. History | 1888 first description by Bruce ('senile rheumatism') → 1957 Barber named it 'polymyalgia rheumatica' → 1963 association with giant cell arteritis established → 2012 ACR/EULAR classification criteria published. |
| 2. Causes | Cause unknown. Complex factors presumed, including genetic predisposition (HLA-DRB1*04), aging-related immune changes, and infectious triggers (parvovirus, influenza). |
| 3. Genetics | Associated with HLA-DRB1*04 (especially *0401, *0404). Polymorphisms of immune-regulatory genes such as IL-6, PTPN22, and TLR4. Shares a genetic background with giant cell arteritis. |
| 4. General epidemiology | Annual incidence about 50~100 per 100,000 population aged 50 and older (highest in Northern Europe and Scandinavia). Incidence relatively low in Korea. Female:male about 2~3:1. |
| 5. Pathophysiology | Innate immune activation centered on IL-6 oversecretion. Toll-like receptor (TLR) activation in dendritic cells and macrophages → Th1/Th17 response → synovitis and bursitis of the shoulder and pelvic girdles. |
| 6. Symptoms | Bilateral pain in the shoulders, neck, pelvic girdle, and thighs with morning stiffness (30 minutes to several hours). Systemic symptoms (fever, fatigue, weight loss). Difficulty raising the arms. No muscle weakness (distinguished from myalgia). |
| 7. Signs | Limited active movement of the shoulder and pelvic girdles (passive movement preserved). ESR >40 mm/hr, markedly elevated CRP. Anemia, mildly elevated ALP. Normal electromyography and muscle biopsy. |
| 8. Screening | No specific screening test. Shoulder and pelvic girdle pain + elevated ESR/CRP at age 50 or older are the key screening indicators. Synovitis and bursitis confirmed by shoulder and pelvic ultrasound. |
| 9. Diagnosis | 2012 ACR/EULAR classification criteria (scoring system): shoulder pain, age, ESR/CRP, morning stiffness, hip pain/limited range of motion, RF/CCP negative, shoulder ultrasound, etc. Diagnostic response to steroids is used. |
| 10. Treatment | Low-dose prednisolone (15~20 mg/day) is the specific standard treatment. Dramatic response (within 24~48 hours). Gradual tapering. Dose increase on relapse. Steroid-sparing with methotrexate combination. Tocilizumab (IL-6 inhibitor) for relapse or refractory disease. |
| 11. Prognosis | Generally good. Most achieve remission with 1~3 years of treatment. Relapse rate about 40~50%. Risk of blindness when giant cell arteritis coexists. Management of long-term steroid adverse effects is important. |
| 12. Prevention | Primary prevention not possible. Prevention of steroid adverse effects (osteoporosis prevention, blood glucose and blood pressure monitoring). Education on symptoms of giant cell arteritis. Early recognition of relapse. |
| 13. References | Dejaco C et al. 2015 recommendations for the management of polymyalgia rheumatica … and 9 other references |
The history of Polymyalgia Rheumatica (PMR) dates back to the late 19th century. In 1888, the British physician William Bruce first described a group of elderly patients with pain in the shoulder and pelvic girdles under the name 'senile rheumatism'. He emphasized that the disease is characterized by inflammation of the muscles and surrounding tissues and occurs only in the elderly aged 50 and older.
The current name was established by the mid-20th century. In 1957, the Scottish physician Hinton Barber first used the term 'polymyalgia rheumatica' for this clinical syndrome characterized by pain and stiffness of the shoulder and pelvic girdles. It is also a paradoxical name, in that although myalgia (muscle pain) at multiple sites is the main symptom, it was later learned that the disease is actually inflammation of synovial structures rather than of the muscles themselves.
In 1963, the association with giant cell arteritis (GCA) began to attract attention. Hamrin et al. described that findings of giant cell arteritis can appear on temporal artery biopsy in PMR patients, and subsequent studies confirmed that GCA accompanies about 10~30% of PMR, and conversely PMR symptoms appear in 40~50% of GCA patients. These two diseases are currently understood to belong to the same pathophysiological spectrum.
In the 1970s~1980s, it was established that low-dose corticosteroids show a specific and dramatic therapeutic effect in PMR. The response in which symptoms improve markedly within 24~48 hours after prednisolone 15~20 mg/day is so characteristic that it was later used as a diagnostic supportive criterion. In the 1990s, ultrasound and MRI were introduced, and it was confirmed by imaging that the pathophysiology of PMR is inflammation of the shoulder bursae (subacromial and subdeltoid bursae) and of the hip synovium and ischial bursae.
In 2012, the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) jointly published the first international classification criteria for PMR. These criteria are a score-based system characterized by optional inclusion of ultrasound findings. In 2015, the joint EULAR/ACR recommendations for the management of PMR were published, standardizing the starting steroid dose, tapering schedule, management of relapse, and criteria for methotrexate combination. In 2023, the IL-6 inhibitor tocilizumab demonstrated significant efficacy in a randomized controlled trial (SAPHYR) in relapsing and refractory PMR, expanding treatment options.
The exact cause of polymyalgia rheumatica is still unknown. The current hypothesis is that in genetically predisposed older adults, environmental stimuli (infections, other immune triggers) activate an abnormal immune response, causing inflammation of the synovium and surrounding structures of the shoulder and pelvic girdles.
Genetic factors: numerous studies have confirmed that HLA-DRB1*04 alleles (especially *0401, *0404) are associated with both PMR and giant cell arteritis. HLA-DRB1*04 encodes an MHC II molecule that presents antigens to CD4+ T cells, and individuals carrying this allele are presumed to be more likely to overreact to certain autoantigens or exogenous antigens. However, because PMR also occurs in HLA-DRB1*04-negative individuals, this allele is merely a risk factor, not a necessary condition.
Infectious triggers: seasonal variation (increased frequency of onset in spring~summer) and epidemic patterns in certain regions suggest the involvement of infectious agents. Parvovirus B19, influenza virus, mycoplasma, chlamydia, and others have been studied as possible associated infectious agents, but no single causative infectious agent has been established. There are reported cases of transient PMR-like symptoms after influenza vaccination, suggesting that immune activation by a vaccine can trigger PMR in predisposed individuals, but causality is not clear.
Aging-related immune changes: the fact that PMR almost never occurs before age 50 suggests that aging-related immune changes (immunosenescence) play an important role in its onset. In old age, decreased regulatory T cell (Treg) function, increased responsiveness of innate immune cells (macrophages, dendritic cells), and changes in the age-related cytokine environment (especially elevated baseline IL-6 levels) appear. IL-6 is the key cytokine in the pathogenesis of PMR; serum IL-6 levels are markedly elevated in patients with active PMR, and it is the main cause of elevated ESR and CRP and of systemic symptoms.
Vascular and synovial abnormalities: recent studies have confirmed that in PMR as well, subacute synovitis of the subacromial and subdeltoid bursae, shoulder joint cavity, hip synovium, and ischial bursae is the key lesion. Synovial infiltration by CD4+ T cells, macrophages, and dendritic cells and secretion of IL-6, IL-1β, and TNF-α are the mechanisms sustaining inflammation. In some PMR, large-vessel PET shows signs of activation, further supporting a continuous spectrum with GCA.
The genetics of polymyalgia rheumatica shares much with giant cell arteritis (GCA). Both diseases are strongly associated with the HLA-DRB1*04 region, which genetically supports the clinical observation that they belong to the same pathophysiological spectrum.
According to the shared epitope theory of HLA-DRB1*04, a specific amino acid sequence in the antigen-binding groove of the MHC II molecule encoded by this allele preferentially presents specific peptides that activate autoreactive T cells, thereby promoting the autoimmune response. HLA-DRB1*0401 and *0404 show the strongest association with PMR.
Outside the HLA region, there are reports that IL-6 gene polymorphisms (especially -174G/C in the promoter region) are associated with PMR and GCA. The IL-6 -174C allele is known to increase IL-6 expression, which is consistent with IL-6 being the key cytokine in the pathogenesis of PMR. In addition, the 1858C/T polymorphism of PTPN22 (protein tyrosine phosphatase non-receptor type 22) and TLR4 (toll-like receptor 4) polymorphisms are also being studied as candidate genes associated with PMR susceptibility.
Some study results showing that the genetic risk of PMR is relatively lower than that of giant cell arteritis suggest that environmental factors may contribute more to PMR than to GCA, or that PMR and GCA may manifest as different clinical phenotypes on the same genetic background depending on differences in environmental factors. To date, no genetic marker specific to PMR alone has been established, and discovery of additional genes through large-scale GWAS is anticipated.
Polymyalgia rheumatica is a disease that occurs only in adults aged 50 and older, with an annual incidence of about 50~100 per 100,000 in the population aged 50 and older. Worldwide, the highest incidence is in Northern Europe and Scandinavia (about 90~112 per 100,000), and it is markedly lower in Southern Europe, Asia, and Africa. These regional differences largely match the frequency of HLA-DRB1*04 alleles.
In the United States, the lifetime risk of developing PMR is estimated at about 2.4% in women and about 1.7% in men. The prevalence is about 700 per 100,000 (age 50 and older), making it the most common systemic inflammatory disease among rheumatic diseases in the population aged 50 and older after rheumatoid arthritis. The female-to-male ratio is about 2~3:1, so it is more common in women, and incidence increases with age. The most common age of onset is 70~79 years.
In East Asia, especially Korea, Japan, and China, the incidence of PMR is markedly lower than in the West. Accurate incidence statistics for Korea are lacking, but in Japan it is about 11~22 per 100,000, about 1/4~1/5 the Western level. This is associated with the lower frequency of HLA-DRB1*04 alleles in East Asia. However, due to the rapid aging of Korean society, the number of PMR patients is increasing.
Comorbidity with giant cell arteritis (GCA) is an important epidemiological issue. GCA may accompany about 10~30% of PMR patients, and PMR accompanies 40~50% of GCA. The co-occurrence of PMR and GCA varies by region, with a high rate in Scandinavia and a low rate in the Mediterranean region. Seasonal variation (increased frequency of onset in spring and summer) and fluctuations in incidence with a cycle of about 5~7 years have been reported in some regions, suggesting the existence of infectious triggers.
The most central role in the pathophysiology of polymyalgia rheumatica is played by abnormal activation of innate immunity centered on IL-6 (interleukin-6) oversecretion. Serum IL-6 levels are markedly elevated in patients with active PMR, and clinical results showing that the IL-6 inhibitor tocilizumab is effective in PMR strongly support this mechanism.
Dendritic cell and macrophage activation: in the synovium and surrounding structures of the shoulder and pelvic girdles, plasmacytoid dendritic cells (pDC) are activated and secrete IFN-α and IFN-β, and myeloid dendritic cells (myeloid DC) secrete IL-6, IL-1β, and IL-18. These cytokines activate CD4+ T cells, promoting Th1 (IFN-γ secretion) and Th17 (IL-17 secretion) responses. Decreased regulatory T cell (Treg) function makes suppression of these responses insufficient.
Role of IL-6: IL-6 stimulates hepatic synthesis of acute-phase reactant proteins (CRP, fibrinogen, serum amyloid A), causing elevated ESR and CRP. It also induces fever via the hypothalamus and promotes skeletal muscle catabolism, causing weight loss and fatigue. Intrasynovial IL-6 promotes angiogenesis and synovial cell proliferation, sustaining bursitis and synovitis.
Synovial and bursal inflammation: ultrasound and MRI studies have confirmed that the key lesions of PMR are inflammation of the shoulder joint (subacromial and subdeltoid bursitis, long head of biceps tenosynovitis, acromioclavicular arthritis) and the hip joint (ischial bursitis, femoral head synovitis). Inflammation of the muscle itself (myositis) is absent or minimal, so electromyography and muscle biopsy are normal. This is why the symptoms of PMR look like 'myalgia' but actually originate from inflammation of periarticular structures.
Continuous spectrum with GCA: in GCA, dendritic cells in the vessel wall are activated via the vasa vasorum of the adventitia, T cell and macrophage infiltration proceeds toward the intima, and giant cell formation, intimal thickening, and vascular stenosis occur. In PMR, similar immune activation is understood to appear mainly confined to synovial structures. In some PMR patients, inflammatory signals are observed in the aorta and major vessels on FDG-PET imaging, showing that the distinction from GCA is not always clear.
The clinical symptoms of polymyalgia rheumatica are relatively typical, so the likelihood of the diagnosis can be recognized as high from an appropriate history alone. Symptoms often appear subacutely over days to weeks, but in some they appear suddenly within hours.
Musculoskeletal symptoms: the most characteristic symptom is bilateral shoulder pain and stiffness. The pain is felt in the shoulder region (including the proximal upper arm) and often radiates to the neck and upper back. Subsequently, the pelvic girdle and thighs are also affected, with pain and stiffness of the hips, groin, and thighs. Bilateral symmetric involvement is the rule, but it may start asymmetrically at first. The pain appears even at rest and is especially severe after prolonged inactivity (on waking in the morning, after prolonged sitting).
Morning stiffness: on waking in the morning, the shoulders, neck, pelvis, and hips are stiff, making normal activity difficult, and characteristically this stiffness lasts 30 minutes or more (usually 1~2 hours or more). This morning stiffness is similar to that in rheumatoid arthritis, but in PMR it is confined to large joints and proximal regions rather than small joints.
Functional impairment: raising the arms above the head (e.g., combing hair, reaching for items on a shelf) is difficult, and dressing is hard. Rising from a seated position and climbing up and down stairs are difficult. This functional impairment is due to pain and stiffness, not muscle weakness, and the fact that pure muscle strength is preserved is an important point of differentiation from myositis and myopathy.
Systemic symptoms: about 40~50% of all patients have fever (usually low-grade, 37.5~38.5℃), fatigue (generalized malaise), decreased appetite, weight loss (several kg), and depressed mood. When systemic symptoms are prominent, differentiation from malignancy, infection, and other inflammatory diseases is needed.
Symptoms of coexisting giant cell arteritis (GCA): when headache (especially temporal), scalp tenderness, jaw claudication (jaw pain when chewing), or visual disturbance (transient monocular vision loss or diplopia) appear, coexisting GCA should be strongly suspected. These symptoms indicate an emergency requiring immediate high-dose steroid administration.
Joint symptoms: some patients may have synovitis of peripheral joints such as the wrists and knees, but unlike rheumatoid arthritis, this appears transiently without erosive changes. Swelling of the hands and feet (remitting seronegative symmetric synovitis with pitting edema, RS3PE syndrome) sometimes accompanies.
The physical signs of polymyalgia rheumatica are not specific, but there are several clinically important characteristic findings.
Range of motion examination: active abduction of the shoulder joint is commonly limited to 90° or less, due to pain. In contrast, the passive range of motion is relatively preserved, which is characteristic of PMR. This helps differentiate it from rotator cuff tear or frozen shoulder. Hip movement (especially internal rotation) may also be limited by pain.
Muscle strength examination: on standard muscle strength testing, strength is normal or nearly normal (excluding apparent weakness due to pain). This is the key point of differentiation from myositis. In myositis, muscle strength is actually decreased and muscle enzymes (CK, aldolase) are elevated. In PMR, CK is normal.
Inflammatory markers: markedly elevated ESR (erythrocyte sedimentation rate) (usually >40 mm/hr, often >60~100 mm/hr) and highly elevated CRP are the characteristic laboratory findings of PMR. However, in about 5~10% of patients ESR may remain normal or borderline, so PMR cannot be excluded on the basis of a normal ESR. CRP is more sensitive and responds faster than ESR and is useful for treatment monitoring. Mild normocytic anemia, mildly elevated ALP (alkaline phosphatase), and reactive thrombocytosis may also appear.
Immunological tests: negativity of rheumatoid factor (RF), anti-CCP antibody, ANA, and ANCA is characteristic of PMR. Their positivity suggests rheumatoid arthritis or other connective tissue diseases in the differential. Negative HLA-B27 helps differentiate it from ankylosing spondylitis and psoriatic arthritis.
Ultrasound findings: on shoulder ultrasound, subacromial bursitis, subdeltoid bursitis, and bicipital tenosynovitis are the characteristic findings of PMR. On hip ultrasound, ischial bursitis and synovial effusion may be observed. Ultrasound is noninvasive and can be performed immediately in the clinic, and an ultrasound item (bilateral shoulder subacromial bursitis or subdeltoid bursitis) was included in the ACR/EULAR 2012 criteria. MRI costs more than ultrasound but is used for more detailed structural evaluation.
There is no universal screening test for polymyalgia rheumatica targeting the general population. However, in older patients aged 50 and older, actively considering PMR and systematically evaluating it when the following clinical picture is present is the key to early diagnosis.
Key clinical screening indicators: in patients aged 50 and older, PMR should be strongly suspected when ① bilateral shoulder pain and stiffness, ② morning stiffness of 30 minutes or more, and ③ marked elevation of ESR or CRP appear together. The combination of these three elements alone confers a fairly high pre-test probability of PMR. In particular, in patients aged 65 and older with unexplained elevation of ESR and CRP, mild anemia, fatigue, and weight loss, PMR should be included in the differential diagnosis.
Basic blood tests: the basic tests to perform in patients with suspected PMR are complete blood count (CBC), ESR, CRP, a biochemistry panel (liver function, renal function, electrolytes, ALP, CK, albumin, aldolase), thyroid function test (TSH), RF, anti-CCP antibody, ANA, and urinalysis. These tests are for confirming the diagnosis of PMR and excluding other diseases (malignancy, infection, other rheumatic diseases).
Ultrasound screening: in patients with shoulder and pelvic girdle pain, ultrasound is very useful for noninvasively confirming synovitis and bursitis, and its importance in screening for and diagnosing PMR is increasing. The combination of subacromial bursitis and long head of biceps tenosynovitis is an ultrasound finding highly specific for PMR.
Exclusion of malignancy: screening to exclude malignancies showing symptoms similar to PMR (shoulder and pelvic girdle pain, weight loss, elevated ESR) (lymphoma, multiple myeloma, muscle metastasis of solid cancers, etc.) is important. Concurrent age-appropriate cancer screening tests (colonoscopy, chest CT, PSA, mammography, etc.) are recommended.
The diagnosis of polymyalgia rheumatica is based on a comprehensive evaluation of clinical symptoms, laboratory findings, and imaging findings, and the 2012 joint ACR/EULAR classification criteria are currently used as the standard.
2012 ACR/EULAR classification criteria: age 50 or older, bilateral shoulder pain, and elevated ESR or CRP are required as mandatory items. If these are met, the following scoring items are evaluated. Without ultrasound (score 0~6): morning stiffness 45 minutes or more (2 points), hip pain or limited range of motion (1 point), negative RF or anti-CCP (2 points), absence of other joint involvement (1 point) — a total of 4 points or more classifies as PMR (sensitivity 68%, specificity 78%). With ultrasound (score 0~8): in addition to the above items, bilateral subacromial bursitis or subdeltoid bursitis or long head of biceps tenosynovitis on shoulder ultrasound (1 point), and synovitis of one hip or bilateral ischial bursitis (1 point) — a total of 5 points or more is PMR (sensitivity 66%, specificity 81%).
Diagnostic response to steroids: marked improvement (70~80% or more) of pain, stiffness, and systemic symptoms within 24~72 hours after prednisolone 15~20 mg/day is a very characteristic response of PMR. Because of the dramatic specificity of this response, the initial steroid response is used as a diagnostic supportive criterion. However, other diseases (rheumatoid arthritis, some malignancies) may also respond partially to steroids, so this alone cannot confirm the diagnosis.
Differential diagnosis: rheumatoid arthritis (especially the elderly-onset type, differentiated by small joint involvement + RF positivity), polymyositis and dermatomyositis (differentiated by muscle weakness + CK elevation), hypothyroidism (differentiated by TSH testing), osteoarthritis (normal ESR/CRP, differentiated by bony changes on imaging), fibromyalgia (normal ESR/CRP, widespread tender points), multiple myeloma and lymphoma (serum protein electrophoresis, bone marrow examination), bacterial infectious arthritis, and other connective tissue diseases must be excluded.
Exclusion of giant cell arteritis: when diagnosing PMR, the presence of headache, scalp tenderness, jaw claudication, and visual symptoms must be checked. If these symptoms are present or extracranial vascular symptoms are suspected, temporal artery biopsy and/or temporal artery ultrasound is performed. If GCA is suspected, immediate administration of high-dose steroids (prednisolone 40~60 mg/day) is required.
The standard treatment of polymyalgia rheumatica is low-dose oral corticosteroids, which is the most effective treatment for PMR and brings the fastest symptom improvement. The 2015 joint EULAR/ACR recommendations provide the evidence base for treatment.
Starting dose: prednisolone 15~20 mg/day (or equivalent dose) is started. In uncomplicated PMR without GCA, doses exceeding 20 mg/day are unnecessary and only increase adverse effects. Conversely, a starting dose of less than 12.5 mg/day may produce an insufficient initial response. The expected response is marked improvement of pain and stiffness within 24~72 hours after starting treatment, with nearly complete resolution of symptoms within 1~2 weeks.
Tapering plan: standard tapering according to the EULAR/ACR recommendations is as follows. Taper to 10 mg/day within 4~8 weeks. Thereafter taper by 1 mg every 4 weeks, with a target treatment duration of at least 12 months. The total duration of treatment is usually 1~3 years. ESR and CRP are followed to confirm improvement of clinical symptoms and normalization of inflammatory markers. If symptoms recur or ESR and CRP rise during tapering, the dose is returned to the previous effective dose.
Methotrexate (MTX) combination: in patients at high risk of relapse (women, very high ESR, likelihood of long-term treatment) or at high risk of steroid adverse effects (diabetes, osteoporosis, hypertension, glaucoma, etc.), methotrexate 7.5~10 mg/week is added early to reduce the steroid dose. Meta-analyses have confirmed that MTX combination reduces relapses and lowers cumulative steroid dose. Concomitant folic acid 1 mg/day or 5 mg/week is essential.
Tocilizumab (IL-6 inhibitor): the 2023 SAPHYR randomized controlled trial demonstrated that it significantly increased the remission rate compared with placebo in patients with relapsing PMR. Based on these results, EULAR conditionally recommends the use of tocilizumab in relapsing or refractory PMR and in patients with severe steroid adverse effects. In Korea, National Health Insurance coverage criteria are still being established.
Management of steroid adverse effects: in elderly PMR patients, adverse effects of long-term corticosteroid administration are a major challenge of treatment. To prevent osteoporosis, calcium (1,000~1,200 mg/day) and vitamin D (800~1,200 IU/day) supplementation along with bone density testing and, if necessary, bisphosphonate administration are recommended. Blood glucose, blood pressure, body weight, and signs of infection are monitored regularly. A proton pump inhibitor is co-administered for gastrointestinal protection.
The overall prognosis of polymyalgia rheumatica is relatively good with appropriate treatment. In most patients, symptoms are rapidly controlled with steroid treatment, and many reach complete remission after 1~3 years of treatment. However, relapse, long-term steroid adverse effects, and the development of giant cell arteritis are important prognostic factors.
Remission rate and duration of treatment: with 1~3 years of treatment, about 50~60% of all patients succeed in discontinuing steroids. The remaining 40~50% experience relapse during steroid tapering and need longer treatment. Reported risk factors for relapse include female sex, high initial ESR (>80 mm/hr), rapid tapering, and accompanying peripheral arthritis. Some patients need maintenance with low-dose steroids for several years.
Development of giant cell arteritis: during the course of PMR, GCA may newly develop, or previously latent GCA may manifest. When GCA coexists, permanent blindness due to anterior ischemic optic neuropathy (AION) is the most dangerous complication, and this is a medical emergency that can occur within hours to days. Therefore, during follow-up of PMR patients, the appearance of headache, jaw claudication, and visual symptoms must be monitored.
Steroid adverse effects: osteoporosis, vertebral compression fractures, diabetes, hypertension, infections (especially pneumonia), cataracts, glaucoma, weight gain, and muscle weakness (steroid myopathy) due to long-term steroid use can be a greater cause of morbidity than PMR itself. Prevention and early management of these adverse effects are key to long-term management.
Mortality: death due to PMR itself is rare. In large cohort studies, the life expectancy of PMR patients does not differ significantly from, or is slightly lower than, that of the general elderly population. Coexisting GCA, cardiovascular disease, and infection are the main causes of death.
Primary prevention of polymyalgia rheumatica (preventing its onset itself) is currently not possible. Prevention strategies focus on early diagnosis, prevention of complications (GCA, steroid adverse effects), and minimization of relapse.
Prevention of steroid adverse effects: osteoporosis prevention measures (calcium, vitamin D, bisphosphonates if needed) are given from the start of treatment. Baseline bone density measurement (DXA scan) is performed and monitored regularly during treatment. Blood glucose, blood pressure, body weight, intraocular pressure, and signs of infection are evaluated regularly. Use of a PPI for gastrointestinal protection is considered. Strategies of using the lowest possible effective dose and reducing the steroid dose with MTX combination are important.
Early detection of developing GCA: all PMR patients are educated about GCA symptoms (headache, scalp tenderness, jaw claudication, visual abnormalities) and instructed to visit a medical institution immediately. When GCA is suspected, immediate steroid dose escalation is decisive in preventing blindness.
Management of relapse: steroid tapering proceeds slowly and stepwise, and the dose is increased immediately when symptoms recur or inflammatory markers rise. In patients with frequent relapses, MTX combination or use of tocilizumab is considered early.
Infection prevention: in elderly patients on steroid treatment, influenza vaccine (annually), pneumococcal vaccine, and herpes zoster vaccine are given to prevent infection. COVID-19 vaccination is also kept up to date.